In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Actinium Pharmaceuticals (ATNM), with a price target of $40.00. The company’s shares closed last Tuesday at $8.37, close to its 52-week low of $6.84.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 42.7% and a 51.0% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Monopar Therapeutics Inc, and Adaptimmune Therapeutics.
Actinium Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $48.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $19.47 and a one-year low of $6.84. Currently, Actinium Pharmaceuticals has an average volume of 210K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.
